[1] |
International Diabetes Federation. IDF diabetes atlas 2021[EB/OL].(2021-12-06)[2022-08-31].
|
[2] |
杨文英. 中国糖尿病的流行特点及变化趋势[J]. 中国科学(生命科学),2018,48(8):812-819.
|
[3] |
|
[4] |
|
[5] |
American Diabetes Association Professional Practice Committee. 9. pharmacologic approaches to glycemic treatment:standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1):S125-143. DOI: 10.2337/dc22-S009.
|
[6] |
|
[7] |
|
[8] |
国家药品监督管理局药品审评中心.关于公开征求《以患者为中心的临床试验实施技术指导原则》(征求意见稿)意见的通知[EB/OL].(2022-08-09)[2022-08-31].
|
[9] |
|
[10] |
高妍. 以患者为中心:应对2型糖尿病的多样性及其挑战[J]. 中华糖尿病杂志,2013,5(7):441-443.
|
[11] |
LV Y Y, REN R, TANG C X,et al. Preferencesfor patients with type 2 Diabetes Mellitus for medications in Shandong Province,China:a discrete choice experiment[J]. Patient Prefer Adherence, 2022, 16:2335-2344. DOI: 10.2147/ppa.s367985.
|
[12] |
|
[13] |
DE BEKKER-GROB E W, SWAIT J D, KASSAHUN H T,et al. Are healthcare choices predictable? The impact of discrete choice experiment designs and models[J]. Value Health, 2019, 22(9):1050-1062. DOI: 10.1016/j.jval.2019.04.1924.
|
[14] |
DE BEKKER-GROB E W,RYAN M,GERARD K. Discrete choice experiments in health economics:a review of the literature[J]. Health Econ,2012,21(2):145-172.
|
[15] |
|
[16] |
GELHORN H L, STRINGER S M, BROOKS A,et al. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK[J]. Diabetes Obes Metab, 2013, 15(9):802-809. DOI: 10.1111/dom.12091.
|
[17] |
PURNELL T S,JOY S,LITTLE E,et al. Patient preferences for noninsulin diabetes medications:a systematic review[J]. Diabetes Care,2014,37(7):2055-2062.
|
[18] |
VON ARX L B, KJEER T. The patient perspective of diabetes care:a systematic review of stated preference research[J]. Patient, 2014, 7(3):283-300. DOI: 10.1007/s40271-014-0057-0.
|
[19] |
DONNAN J R,JOHNSTON K,CHIBRIKOV E,et al. Capturing adult patient preferences toward benefits and risks of second-line antihyperglycemic medications used in type 2 diabetes:a discrete choice experiment[J]. Can J Diabetes,2020,44(1):6-13.
|
[20] |
OZDEMIR S, BAID D, VERGHESE N R,et al. Patient preferences for medications in managing type 2 diabetes mellitus:a discrete choice experiment[J]. Value Health, 2020, 23(7):842-850. DOI: 10.1016/j.jval.2020.01.023.
|
[21] |
IGARASHI A, BEKKER HANSEN B, LANGER J,et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes:a discrete choice experiment[J]. Adv Ther, 2021, 38(1):721-738. DOI: 10.1007/s12325-020-01561-1.
|
[22] |
JIA W,WENG J,ZHU D,et al. Chinese Diabetes Society.Standards of medical care for type 2 diabetes in China 2019[J].Diabetes Metab Res Rev,2019,35(6):e3158.
|
[23] |
DOYLE-DELGADO K,CHAMBERLAIN J J,SHUBROOK J H,et al. Pharmacologic approaches to glycemic treatment of type 2 diabetes:synopsis of the 2020 American diabetes association's standards of medical care in diabetes clinical guideline[J]. Ann Intern Med,2020,173(10):813-821.
|
[24] |
ORME B K. Getting started with conjoint analysis:strate-gies for product design and pricing research[M]. 3rd ed.Madison:Research Publishers LLC,2014.
|
[25] |
MOOR S E, TUSUBIRA A K, WOOD D,et al. Patient preferences for facility-based management of hypertension and diabetes in rural Uganda:a discrete choice experiment[J]. BMJ Open, 2022, 12(7):e059949. DOI: 10.1136/bmjopen-2021-059949.
|
[26] |
LIU S M, LIU J, SI L,et al. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China:findings from a national survey[J]. BMJ Glob Health, 2023, 8(4):e010942. DOI: 10.1136/bmjgh-2022-010942.
|
[27] |
LIU S M, LIU J, YU Y J,et al. What is valued most by patients with type 2 diabetes mellitus when selecting second-line antihyperglycemic medications in China[J]. Front Pharmacol, 2021, 12:802897. DOI: 10.3389/fphar.2021.802897.
|
[28] |
RYDÉN A,CHEN S,FLOOD E,et al. Discrete choice experiment attribute selection using a multinational interview study:treatment features important to patients with type 2 diabetes mellitus[J]. Patient,2017,10(4):475-487.
|
[29] |
BROOKS A,LANGER J,TERVONEN T,et al. Patient preferences for GLP-1 receptor agonist treatment of type 2 diabetes mellitus in Japan:a discrete choice experiment[J]. Diabetes Ther,2019,10(2):735-749.
|
[30] |
FORSANDER G, STALLKNECHT S, SAMUELSSON U,et al. Preferences for treatment among adolescents with Type 1 diabetes:a national study using a discrete choice experiment model[J]. Diabet Med, 2018, 35(5):621-629. DOI: 10.1111/dme.13592.
|
[31] |
IGARASHI A, BEKKER HANSEN B, LANGER J,et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with Type 2 diabetes:a discrete choice experiment[J]. Adv Ther, 2021, 38(1):721-738. DOI: 10.1007/s12325-020-01561-1.
|
[32] |
GÓMEZ-PERALTA F, MAREQUE M, MUÑOZ Á,et al. Patient preferences for pharmacological diabetes treatment among people with diabetes in Spain:a discrete choice experiment[J]. Diabetes Ther, 2022, 13(1):75-87. DOI: 10.1007/s13300-021-01178-9.
|
[33] |
SCHOENBORN N L, CROSSNOHERE N L, BRIDGES J F P,et al. Patient perceptions of diabetes guideline frameworks for individualizing glycemic targets[J]. JAMA Intern Med, 2019, 179(12):1642-1649. DOI: 10.1001/jamainternmed.2019.3806.
|
[34] |
AHMAD A, KHAN M U, ASLANI P. Patient preferences for the treatment of type 2 diabetes in Australia:a discrete choice experiment[J]. J Diabetes Metab Disord, 2022, 21(1):229-240. DOI: 10.1007/s40200-021-00962-5.
|
[35] |
MÜHLBACHER A C, SADLER A, JUHNKE C. Personalized diabetes management:what do patients with diabetes mellitus prefer? A discrete choice experiment[J]. Eur J Health Econ, 2021, 22(3):425-443. DOI: 10.1007/s10198-021-01264-6.
|
[36] |
洪天配,杨进. 低血糖症:糖尿病患者血糖控制的主要障碍[J]. 中华糖尿病杂志,2016,8(7):392-395.
|
[37] |
|
[38] |
SHUBROOK J H, RADIN M, ALI S N,et al. Preference for type 2 diabetes therapies in the United States:a discrete choice experiment[J]. Adv Ther, 2022, 39(9):4114-4130. DOI: 10.1007/s12325-022-02181-7.
|
[39] |
MORILLAS C,FELICIANO R,FERNANDEZ CATALINA P,et al. Patient's and professional's preferences for type 2 diabetes mellitus treatments (T2DM) in Spain and Portugal. A discrete choice experiment[J]. Value Heath,2015,18(3):A66.
|
[40] |
PICHÉ M E, TCHERNOF A, DESPRÉS J P. Obesity phenotypes,diabetes,and cardiovascular diseases[J]. Circ Res, 2020, 126(11):1477-1500. DOI: 10.1161/CIRCRESAHA.120.316101.
|
[41] |
|